

# Ming Shi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7135976/publications.pdf>

Version: 2024-02-01

14  
papers

1,728  
citations

933264

10  
h-index

1058333

14  
g-index

15  
all docs

15  
docs citations

15  
times ranked

2670  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunological and inflammatory profiles in mild and severe cases of COVID-19. <i>Nature Communications</i> , 2020, 11, 3410.	5.8	328
2	Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 112-120.	1.4	294
3	Human Mesenchymal Stem Cell Transfusion Is Safe and Improves Liver Function in Acute-on-Chronic Liver Failure Patients. <i>Stem Cells Translational Medicine</i> , 2012, 1, 725-731.	1.6	287
4	Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 172.	7.1	236
5	Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 58.	7.1	178
6	A pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 85-92.	1.4	153
7	A Pilot Study of Mesenchymal Stem Cell Therapy for Acute Liver Allograft Rejection. <i>Stem Cells Translational Medicine</i> , 2017, 6, 2053-2061.	1.6	86
8	Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial. <i>EBioMedicine</i> , 2022, 75, 103789.	2.7	60
9	Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial. <i>Hepatology International</i> , 2021, 15, 1431-1441.	1.9	51
10	The Ratio of Circulating Regulatory T Cells (Tregs)/Th17 Cells Is Associated with Acute Allograft Rejection in Liver Transplantation. <i>PLoS ONE</i> , 2014, 9, e112135.	1.1	23
11	Characteristics of VÎ1+ and VÎ2+ Î³Î T cell subsets in acute liver allograft rejection. <i>Transplant Immunology</i> , 2013, 29, 118-122.	0.6	10
12	A pilot study on the characteristics of circulating T follicular helper cells in liver transplant recipients. <i>Transplant Immunology</i> , 2018, 47, 32-36.	0.6	9
13	Circulating CXCR3-CCR6-CXCR5+CD4+ T cells are associated with acute allograft rejection in liver transplantation. <i>Immunology Letters</i> , 2019, 213, 55-61.	1.1	5
14	Diagnosis and Treatment Guidelines for Mesenchymal Stem Cell Therapy for Coronavirus Disease 2019 (Beijing, 2021). <i>Infectious Diseases &amp; Immunity</i> , 2021, 1, 68-73.	0.2	5